NCT06311045View on ClinicalTrials.gov

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

NARecruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions
Obstructive Sleep Apnea
Interventions
DIETARY_SUPPLEMENT

N-acetylcysteine (NAC)

Participants will take two NAC 600mg capsules daily for four weeks.

DIETARY_SUPPLEMENT

Placebo

Participants will take two placebo 600mg capsules daily for four weeks.

PROCEDURE

Positive Airway Pressure (PAP) Therapy

All participants will receive PAP therapy per standard of care for OSA.

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

NYU Langone Health

OTHER